Atezolizumab with platinum-based chemotherapy and bevacizumab for epithelial ovarian cancer or fallopian tube cancer or primary peritoneal cancer

Atezolizumab in combination with bevacizumab and chemotherapy is currently in clinical
development for the treatment of patients with epithelial ovarian cancer or primary peritoneal
or fallopian tube cancer. Epithelial ovarian cancers are the most common type of ovarian cancer.
Primary peritoneal cancer and fallopian tube cancer are similar to epithelial ovarian cancer. All
three types show signs of pain and swelling in the abdominal area. Other signs and symptoms
include frequent urge to urinate, trouble eating, bloating or constipation. The optimal treatment
strategy for women with platinum sensitive ovarian cancer has yet to be determined.